Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02397811 · ClinicalTrials.gov registry record · NA
Astaxanthin Formulation Bioavailability
A NA study of Bioavailability of Astaxanthin Formulations, sponsored by Cyanotech Corporation.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02397811: Completed NA study of Bioavailability of Astaxanthin Formulations, sponsored by Cyanotech Corporation.
NCT02397811 is a NA study of Bioavailability of Astaxanthin Formulations that has completed, run by Cyanotech Corporation. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02397811, a NA study of Bioavailability of Astaxanthin Formulations, has completed, sponsored by Cyanotech Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Human crossover pharmacokinetic study involving 12 subjects to determine the relative bioavailability of astaxanthin in six commercially available oral formulations.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Enteric Coated Softgels
- DIETARY_SUPPLEMENT Liposomal astaxanthin
- DIETARY_SUPPLEMENT Standard Softgel
- DIETARY_SUPPLEMENT Astaxanthin Water Soluble Emulsion
- DIETARY_SUPPLEMENT Astaxanthin Water Dispersible Powder
Study Locations (1)
Florida
- USF Health: College of Medicine - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT02397811 record still lists
NCT02397811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Bioavailability of Astaxanthin Formulations appearing as the primary indexed condition, and to 5 interventions - of which Enteric Coated Softgels is the first listed.
NCT02397811 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02397811 about?
NCT02397811 is a clinical study titled "Astaxanthin Formulation Bioavailability". Human crossover pharmacokinetic study involving 12 subjects to determine the relative bioavailability of astaxanthin in six commercially available oral formulations.
What is the current status of trial NCT02397811?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2015-06. Estimated completion is 2015-12.
What conditions does trial NCT02397811 study?
This clinical trial studies the following conditions: Bioavailability of Astaxanthin Formulations.
What interventions are being tested in trial NCT02397811?
The interventions under investigation include: Enteric Coated Softgels (DIETARY_SUPPLEMENT), Liposomal astaxanthin (DIETARY_SUPPLEMENT), Standard Softgel (DIETARY_SUPPLEMENT), Astaxanthin Water Soluble Emulsion (DIETARY_SUPPLEMENT), Astaxanthin Water Dispersible Powder (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02397811?
This trial is sponsored by Cyanotech Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02397811 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02397811's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia